Compare Moderna, Inc. (MRNA) vs Oatly Group AB - ADR (OTLY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moderna, Inc. vs Oatly Group AB - ADR — how do they compare? Moderna, Inc. trades at $225 (market cap $78.65B), while Oatly Group AB - ADR trades at $10.59 (market cap $330.93M). The key difference: Moderna, Inc. is far larger — about 237.7× Oatly Group AB - ADR's market cap, and Moderna, Inc. is trading nearer its 52-week high, Oatly Group AB - ADR nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Moderna, Inc. for 59 Days and Oatly Group AB - ADR for 18 Days on average.
| MRNA | OTLY | |
|---|---|---|
Market Cap | $78.65B | $330.93M |
Volume | 37,373,437 | 68,708 |
Sector | Health | Consumer Staples |
52-Week High | $203.46 | $15.91 |
52-Week Low | $22.36 | $8.03 |
Typical Hold Time | 59 Days | 18 Days |
Enterprise Value | $74.80B | $835.34M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Moderna (MRNA) trades at $197.00, up 0.26% on the day, with technical indicators showing a bullish trend and strong momentum. The stock has rallied over 500% in 2026, driven by positive clinical updates for its cancer vaccine pipeline and inclusion in the Nasdaq-100 index effective October 9, 2026. However, fundamentals remain challenging with revenue declining from $18.9B in 2022 to $1.9B in 2025 and negative net income margins exceeding 140%.
While technical momentum and pipeline optimism support near-term upside, valuation appears stretched with P/S of 35.08 and negative profitability metrics. Key risks include execution on non-COVID products, competitive pressure, and sustainability of recent gains. Analyst consensus is cautious with only 28% buy ratings and $115.70 price target suggesting significant downside from current levels.
OTLY trades at $10.38 with minimal daily movement (+0.1%). The stock shows mixed signals with a bearish technical outlook but improving fundamentals. Recent Q2 2026 results showed revenue growth and margin improvement, though the company continues to post net losses. Analyst sentiment is divided with a $12.28 consensus target, representing 18% upside potential from current levels.
The investment case hinges on Oatly's ongoing turnaround efforts showing progress through revenue growth and margin expansion. Key risks include persistent negative cash flow, high debt levels, and delayed profitability. The stock offers speculative appeal for investors betting on the plant-based beverage market growth and operational improvements, but requires careful risk management.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →About Oatly Group AB - ADR
Oatly Group AB is engaged in the food and drinks industry. Some of its products include Oat Drink, Chilled Oat Drink, Oatgurt, Creamy Oat, Icecreams, among others. It caters to Sweden, Germany, United Kingdom, Netherlands, North America, Finland, and other markets.
Read more on OTLY →
